ArticleMolecular cancer therapeutics2012

The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.

Rupashree Sen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.